Patents written and products formulated by
Dr. Timothy M. Marshall, Ph.D.
FoodPharma’s Chief Science Officer
Neuropharmacologist, Nutritional Biochemist
Fusing the best of nutritional delivery into a single powerful vehicle – our QuadOral™ Absorption Technology – utilizes powerful permeation enhancers that efficiently deliver small molecule nutrients into the bloodstream when chewed and swallowed so they can be distributed to their active sites of action. Perfect for a wide range of nutritional applications (e.g. memory / focus, mood / occasional stress relief, cardiovascular support, gastrointestinal / weight loss management support).
SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NEUROTROPHIC AND NEUROPROTECTIVE COMPOSITIONS
 This application claims priority from United States Provisional Patent Application No.62/696,995, filed July 12, 2018 and entitled “A NOVEL, SACCHARIDE-BASED, ORAL MUCOADHESIVE DELIVERY SYSTEM FOR FAST-ACTING, NEUROTROPHIC AND NEUROPROTECTIVE BENEFITS,” the disclosures of which are hereby incorporated entirely herein by reference.
 This invention generally relates to delivery systems, and more particularly to a saccharide- based oral mucoadhesive delivery system for administration of neurotrophic and neuroprotective compositions.
 The oral cavity is an ideal-site for small molecule, nutrient/nutraceutical delivery to the central nervous system (CNS) and systemic circulation due to the highly-vascularized, oral mucosa, near-neutral pH conditions, close proximity to the brain, and avoidance of gastric degradation and the first-pass effect. The rich-blood supply of the oral mucosa and “sticky”, mucoadhesive properties of this novel, saccharide-based, delivery system allows for the efficient absorption of small molecules across several highly-vascularized surfaces including the gingival, sublingual, soft-palatal, and buccal mucosa. Herein, I introduce a novel, saccharide-based, food-form, palatable, easy-to-administer, oral delivery system that attaches to these four, highly-absorptive surfaces for a longer contact-duration than current orally-available formulas resulting in greater, small molecule bioavailability, and a more rapid, therapeutic effect. This invention represents the next-generation in optimized, highly- efficacious, small molecule delivery systems for CNS-related conditions that moves one-step closer in approximating intravenous injection in systemic bioavailability and therapeutic onset.